New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
05:55 EDTABMD, ABMD, ABMD, ANGO, ANGO, ANGO, BAX, BAX, BAX, BDX, BDX, BDX, CAH, CAH, CAH, COV, COV, COV, EW, EW, EW, NVO, NVO, NVO, SYK, SYK, SYKSociety of Thoracic Surgeons to hold annual meeting
49th Annual Meeting of the STS is being held in Los Angeles on January 26-30.
News For ABMD;ANGO;BAX;BDX;CAH;COV;EW;NVO;SYK From The Last 14 Days
Check below for free stories on ABMD;ANGO;BAX;BDX;CAH;COV;EW;NVO;SYK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
07:01 EDTCOVCovidien acquires Reverse Medical, terms not disclosed
Subscribe for More Information
August 21, 2014
15:37 EDTBAXNektar: Baxter announces positive results from Phase 3 study of BAX 855
Nektar Therapeutics (NKTR) reports Baxter International (BAX) announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95 percent reduction in median ABR as compared to those in the on-demand arm (1.9 vs. 41.5, respectively). BAX 855 was also effective in treating bleeding episodes, 96 percent of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 - 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study
09:02 EDTBAXBaxter announces BAX 855 met primary endpoint in Phase 3 study
Baxter announced "positive" results from its Phase 3 pivotal clinical trial of BAX 855, which met its primary endpoint in reducing annualized bleed rates in the prophylaxis arm compared to the on-demand arm. Top-line results from the prospective, global, multi-center Phase 3 study demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older. Patients in a twice-weekly prophylaxis arm experienced a 95% reduction in median ABR as compared to those in the on-demand arm. BAX 855 was also effective in treating bleeding episodes, 96% of which were controlled with one or two infusions. The half-life of BAX 855 was 1.4 – 1.5 times that of ADVATE, consistent with the findings from the Phase 1 study. No patients developed inhibitors to BAX 855 and no treatment-related serious adverse events, including hypersensitivity, were reported. The most common product-related adverse event was headache. Baxter expects to submit a Biologics License Application for BAX 855 to the U.S. Food and Drug Administration before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study.
08:29 EDTEWEdwards Lifesciences price target raised to $120 from $97 at JMP Securities
Subscribe for More Information
August 20, 2014
07:18 EDTCOVMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
16:33 EDTBAXBaxter to expand Alabama facility to increase dialyzers production
Subscribe for More Information
08:22 EDTCOVMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
August 18, 2014
16:10 EDTCOVCovidien says study shows directional atherectomy safe, effective
Covidien announced that directional atherectomy is "safe and effective as a frontline therapy for the treatment of peripheral arterial disease," according to a Covidien study published online today in the Journal of American College of Cardiology, Cardiovascular Interventions. Results from the DEFINITIVE LE study using Covidien’s TurboHawk and/or SilverHawk directional atherectomy systems demonstrated 95% limb salvage in patients with critical limb ischemia and 78% overall patency in claudicant patients at 12 months.
August 14, 2014
17:16 EDTCOVPaulson & Co gives quarterly update on stakes
Subscribe for More Information
11:34 EDTANGOAngioDynamics backs FY15 adjusted EPS view 64c-70c, consensus 39c
Subscribe for More Information
11:28 EDTANGOAngioDynamics backs Q1 EPS view 8c-12c, consensus 5c
Backs Q1 revenue view $83M-$86M, consensus $85.33M. Guidance from slides presentation.
08:07 EDTBAXKamada sees FY14 revenue $70M-$72M, consensus $75.4M
Kamada (KMDA) expects FY14 revenue $70M-$72M, with revenue from its Distribution Segment projected to be between $25M-$26M and revenue from its Proprietary Products Segment to be between $45M-$47M. The company notes that U.S. revenues from the agreement with Baxter (BAX) remain on track.
07:27 EDTCOVJPMorgan a buyer of Medtronic at current levels
Subscribe for More Information
06:15 EDTCOVCovidien risk/reward very favorable, says Citigroup
Subscribe for More Information
August 12, 2014
10:00 EDTSYKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:22 EDTSYKStryker upgraded to Buy from Hold at Needham
Subscribe for More Information
August 11, 2014
16:21 EDTCAHCardinal Health, Fred's announce primary supply agreement
Subscribe for More Information
15:25 EDTABMDStephens to hold a bus trip
Subscribe for More Information
11:58 EDTNVOMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use